Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The Series C funding will be used to advance the company’s novel oral p300/CBP inhibitor, inobrodib, for the treatment of multiple myeloma.
read more
RJx-01 is an orally administered proprietary combination drug that has the potential to meaningfully address sarcopenia.
read more
The new platform is based on an optimized design of experiments, a statistical approach to process and reaction condition optimization.
read more
Key to the $470M deal is Vigil’s VG-3927, an oral small molecule TREM2 agonist.
read more
According to TurtleTree, this marks the first time any regulatory body has approved the bioactive milk protein produced through precision fermentation.
read more
The company is focused on treatments for patients suffering from major depressive disorder, Alzheimer’s disease, schizophrenia and other synaptopathies.
read more
Key to the deal is STC-004, a phase 2 ready oral Nav1.8 inhibitor being studied for the treatment of pain
read more
The company has dosed the first patient in the 10,000-person portion of its ongoing phase 2b clinical trial evaluating its oral pill COVID vaccine candidate.
read more
AstraZeneca has agreed to settle a class action lawsuit accusing the company of scheming to block generic competition to its antipsychotic drug.
read more
The proactive approach exemplifies a new treatment strategy in oncology, redefining how we think about drug resistance in breast cancer.
read more
Bayer’s oral androgen receptor inhibitor, Nubeqa, in combination with ADT, is now approved for metastatic castration-sensitive prostate cancer.
read more
Nugevia products will bring a clinical-grade standard to the nutraceutical space.
read more
Enlicitide demonstrated statistically significant and clinically meaningful reductions in cholesterol in a pair of phase 3 trials.
read more
Widaplik is the first and only FDA-approved triple combo med for use as initial therapy in patients who need multiple drugs to achieve blood pressure goals.
read more
In total, two phase 2/3 trials are included in the hold, as well as three additional phase 1 trials of either agent and/or their combinations.
read more